These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 33120845)

  • 1. Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
    Wang L; Yan X; He J
    Medicine (Baltimore); 2020 Oct; 99(43):e22923. PubMed ID: 33120845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of atypical acute promyelocytic leukaemia: Three cases report and literature review.
    Wang X; Wang J; Zhang L
    Medicine (Baltimore); 2019 May; 98(19):e15537. PubMed ID: 31083206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
    Sasaki K; Ravandi F; Kadia T; DiNardo CD; Yilmaz M; Short N; Jabbour E; Patel KP; Loghavi S; Pierce S; Borthakur G; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):375-381. PubMed ID: 38431521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
    Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy.
    Peterson JF; He RR; Nayer H; Cuevo RS; Smadbeck JB; Vasmatzis G; Greipp PT; Ketterling RP; Hoppman NL; Baughn LB
    Cancer Genet; 2019 Sep; 237():51-54. PubMed ID: 31447065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
    Park YH; Kim DY; Mun YC; Cho EK; Lee JH; Jo DY; Kim I; Yoon SS; Park SY; Kim B; Bang SM; Kim H; Min YJ; Park JH; Seo JJ; Moon HN; Lee MH; Kim CS; Lee WS; Chong SY; Oh D; Zang DY; Lee KH; Hyun MS; Kim HS; Kim SH; Kwon H; Kim HJ; Park KT; Bae SH; Ryoo HM; Choi JH; Ahn MJ; Yoon HJ; Nam SH; Kim BS; Seong CM
    Korean J Intern Med; 2022 Jul; 37(4):841-850. PubMed ID: 35811370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid.
    Burry LD; Seki JT
    Ann Pharmacother; 2002 Dec; 36(12):1900-6. PubMed ID: 12452754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.
    Li Y; Yu J; Xu Q; Zhang K
    Medicine (Baltimore); 2021 Dec; 100(48):e28076. PubMed ID: 35049232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of acute promyelocytic leukemia relapse in the ATRA era.
    Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
    Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases.
    Liso V; Specchia G; Pogliani EM; Palumbo G; Mininni D; Rossi V; Teruzzi E; Mestice A; Coppi MR; Biondi A
    Cancer; 1998 Oct; 83(8):1522-8. PubMed ID: 9781945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine, cytarabine: A case report and literature review.
    Zhang G; Song Y; Wan L; Liu K; Qiu S; Wang J; Mi Y
    Blood Sci; 2022 Apr; 4(2):93-96. PubMed ID: 35957665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
    Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
    Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of acute promyelocytic leukaemia using a combination of all-trans retinoic acid and chemotherapy.
    Koh LP; Goh YT; Teoh G; Tan P
    Ann Acad Med Singap; 2001 Jul; 30(4):401-8. PubMed ID: 11503549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
    Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
    Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Henzan H; Takase K; Kamimura T; Mori Y; Yoshimoto G; Iwasaki H; Nagafuji K; Ogawa R; Eto T; Uchida N; Fujisaki T; Kato K; Minami M; Kikushige Y; Akashi K; Miyamoto T;
    Int J Hematol; 2020 Sep; 112(3):349-360. PubMed ID: 32524309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.
    Dang CC; Guan YK; Lau NS; Chan SY
    J Oncol Pharm Pract; 2020 Dec; 26(8):2034-2037. PubMed ID: 32279594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
    Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
    Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.